After the hypoglycaemia induction experiment until 2 weeks after the double icodec dose, until 1 week after the triple icodec dose and until 48 h after the glargine U100 double and triple doses (i.e. the longest possible assessment period with no other potentially confounding insulin administration), the mean percentage time spent below range based on CGM recordings was well below the consensus guidance clinical targets for CGM data of <1% of time spent with glucose <3.0 mmol/l and <4% of time spent with glucose <3.9 mmol/l [20, 21]. The gene discussed is INS; the disease is Hypoglycemia.